{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:16:51Z","timestamp":1786997811789,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tumour Virus Research"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.tvr.2023.200263","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T10:33:30Z","timestamp":1686134010000},"page":"200263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Is immunotherapy a potential game changer in managing human papillomavirus (HPV) infection and intraepithelial neoplasia?"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0604-9097","authenticated-orcid":false,"given":"Peter L.","family":"Stern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tvr.2023.200263_bib1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1470-2045(18)30836-2","article-title":"Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study","volume":"20","author":"Simms","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.tvr.2023.200263_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/14760584.2019.1568876","article-title":"Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies","volume":"18","author":"Lehtinen","year":"2019","journal-title":"Expert Rev. Vaccines"},{"issue":"2","key":"10.1016\/j.tvr.2023.200263_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrclinonc.2015.146","article-title":"HPV-FASTER: broadening the scope for prevention of HPV-related cancer","volume":"13","author":"Bosch","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.tvr.2023.200263_bib4","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1016\/S2214-109X(22)00241-8","article-title":"Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis","volume":"10","author":"Bruni","year":"2022","journal-title":"Lancet Global Health"},{"issue":"8","key":"10.1016\/j.tvr.2023.200263_bib5","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/ijc.34384","article-title":"ESTAMPA study group. Performance of visual inspection of the cervix with acetic acid (VIA) for triage of HPV screen-positive women: results from the ESTAMPA study","volume":"152","author":"Baena","year":"2023","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.tvr.2023.200263_bib6","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jnci\/djaa011","article-title":"Costa Rica HPV vaccine trial (CVT) group. Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Kreimer","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.tvr.2023.200263_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100056","article-title":"Efficacy of single-dose HPV vaccination among young African women","volume":"1","author":"Barnabas","year":"2022","journal-title":"NEJM Evid"},{"issue":"1","key":"10.1016\/j.tvr.2023.200263_bib8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s13063-021-05608-8","article-title":"Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial","volume":"22","author":"Barnabas","year":"2021","journal-title":"Trials"},{"issue":"10","key":"10.1016\/j.tvr.2023.200263_bib9","doi-asserted-by":"crossref","first-page":"e1485","DOI":"10.1016\/S2214-109X(22)00306-0","article-title":"Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial","volume":"10","author":"Baisley","year":"2022","journal-title":"Lancet Global Health"},{"issue":"3","key":"10.1016\/j.tvr.2023.200263_bib11","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jnci\/djac189","article-title":"Public health opportunities resulting from sufficient HPV vaccine supply and a single-dose vaccination schedule","volume":"115","author":"Kreimer","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.tvr.2023.200263_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/diagnostics13020243","article-title":"Updates on HPV vaccination","volume":"13","author":"Illah","year":"2023","journal-title":"Diagnostics"},{"issue":"41","key":"10.1016\/j.tvr.2023.200263_bib13","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1016\/j.vaccine.2022.08.020","article-title":"Therapeutic HPV Vaccine PPC Expert Consultation Group. Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: world Health Organization consultations","volume":"40","author":"Prudden","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.tvr.2023.200263_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.coviro.2021.09.014","article-title":"Principles of epithelial homeostasis control during persistent human papillomavirus infection and its deregulation at the cervical transformation zone","volume":"51","author":"Doorbar","year":"2021","journal-title":"Curr Opin Virol"},{"issue":"3","key":"10.1016\/j.tvr.2023.200263_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2051013617717914","article-title":"Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy","volume":"5","author":"Smola","year":"2017","journal-title":"Ther Adv Vaccines"},{"issue":"1","key":"10.1016\/j.tvr.2023.200263_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008206","article-title":"Stress keratin 17 enhances papillomavirus infection-induced disease by downregulating T cell recruitment","volume":"16","author":"Wang","year":"2020","journal-title":"PLoS Pathog."},{"issue":"43","key":"10.1016\/j.tvr.2023.200263_bib17","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1038\/onc.2016.102","article-title":"Loss of Keratin 17 induces tissue-specific cytokine polarization and cellular differentiation in HPV16-driven cervical tumorigenesis in vivo","volume":"35","author":"Hobbs","year":"2016","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.tvr.2023.200263_bib18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214225120","article-title":"Stress keratin 17 and estrogen support viral persistence and modulate the immune environment during cervicovaginal murine papillomavirus infection","volume":"120","author":"Wang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.tvr.2023.200263_bib19","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.cell.2023.03.005","article-title":"Cancer immunotherapy: T cells and neutrophils working together to attack cancers","volume":"186","author":"Ager","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.tvr.2023.200263_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.tvr.2023.200263_bib21","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","article-title":"A neutrophil response linked to tumor control in immunotherapy","volume":"186","author":"Gungabeesoon","year":"2023","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.tvr.2023.200263_bib22","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","article-title":"T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants","volume":"186","author":"Hirschhorn","year":"2023","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.tvr.2023.200263_bib23","doi-asserted-by":"crossref","first-page":"7107","DOI":"10.4049\/jimmunol.1002756","article-title":"Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium","volume":"185","author":"Trimble","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.tvr.2023.200263_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2019.12.002","article-title":"The human papillomavirus 16 E5 gene potentiates MmuPV1-Dependent pathogenesis","volume":"541","author":"Torres","year":"2020","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.tvr.2023.200263_bib25","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/ijc.34128","article-title":"Different human papillomavirus types share early natural history transitions in immunocompetent women","volume":"151","author":"Adebamowo","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.tvr.2023.200263_bib26","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1002\/ijc.31883","article-title":"Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types","volume":"144","author":"Sand","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.tvr.2023.200263_bib27","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3390\/vaccines10091560","article-title":"The effectiveness of therapeutic vaccines for the treatment of cervical intraepithelial neoplasia 3: a systematic review and meta-analysis","volume":"10","author":"Ventura","year":"2022","journal-title":"Vaccines"},{"issue":"10008","key":"10.1016\/j.tvr.2023.200263_bib28","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.tvr.2023.200263_bib29","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1080\/21645515.2020.1823778","article-title":"Durability of response to VGX-3100 treatment of HPV16\/18 positive cervical HSIL","volume":"17","author":"Bhuyan","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"issue":"2","key":"10.1016\/j.tvr.2023.200263_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/v14020239","article-title":"Therapeutic DNA vaccines against HPV-related malignancies: promising leads from clinical trials","volume":"14","author":"Tang","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.tvr.2023.200263_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2022.105747","article-title":"Combination therapy between prophylactic and therapeutic human papillomavirus (HPV) vaccines with special emphasis on implementation of nanotechnology","volume":"171","author":"Gohar","year":"2022","journal-title":"Microb. Pathog."},{"issue":"1","key":"10.1016\/j.tvr.2023.200263_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55014-z","article-title":"A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins","volume":"9","author":"Hancock","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.tvr.2023.200263_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000493737","article-title":"Human papillomavirus and genital disease in men: what we have learned from the HIM study","volume":"63","author":"Sichero","year":"2019","journal-title":"Acta Cytol."},{"issue":"5","key":"10.1016\/j.tvr.2023.200263_bib36","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","article-title":"HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management","volume":"19","author":"Lechner","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.tvr.2023.200263_bib37","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jadohealth.2011.03.010","article-title":"Age-specific prevalence of human papillomavirus infection in males: a global review","volume":"48","author":"Smith","year":"2011","journal-title":"J. Adolesc. Health"},{"issue":"1","key":"10.1016\/j.tvr.2023.200263_bib38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/infdis\/jiab334","article-title":"Prevalence of human papillomavirus among women older than recommended age for vaccination by birth cohort, United States 2003\u20122016","volume":"225","author":"Vahle","year":"2022","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.tvr.2023.200263_bib39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ijc.34269","article-title":"Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: a worldwide analysis","volume":"152","author":"Deshmukh","year":"2023","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.tvr.2023.200263_bib40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ijc.33185","article-title":"A meta-analysis of anal cancer incidence by risk group: toward a unified anal cancer risk scale","volume":"148","author":"Clifford","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tvr.2023.200263_bib41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pvr.2015.06.007","article-title":"Seroconversion following anal and genital HPV infection in men: the HIM study","volume":"1","author":"Giuliano","year":"2015","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.tvr.2023.200263_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bpobgyn.2017.08.006","article-title":"Epidemiology and burden of HPV-related disease","volume":"47","author":"Serrano","year":"2018","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"9","key":"10.1016\/j.tvr.2023.200263_bib43","doi-asserted-by":"crossref","first-page":"e531","DOI":"10.1016\/S2352-3018(21)00108-9","article-title":"Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies","volume":"8","author":"Wei","year":"2021","journal-title":"Lancet HIV"},{"issue":"7","key":"10.1016\/j.tvr.2023.200263_bib44","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/DCR.0000000000001114","article-title":"Prepared on behalf of the clinical practice guidelines committee of the American society of colon and rectal surgeons. The American society of colon and rectal surgeons clinical practice guidelines for anal squamous cell cancers (revised 2018)","volume":"61","author":"Stewart","year":"2018","journal-title":"Dis. Colon Rectum"},{"issue":"11","key":"10.1016\/j.tvr.2023.200263_bib45","doi-asserted-by":"crossref","first-page":"e3572","DOI":"10.1093\/cid\/ciaa1391","article-title":"Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV medicine association of the infectious diseases society of America","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.tvr.2023.200263_bib46","first-page":"183","article-title":"Current treatment and future directions in the management of anal cancer","volume":"72","author":"Tchelebi","year":"2022","journal-title":"Ca - Cancer J. Clin."},{"issue":"24","key":"10.1016\/j.tvr.2023.200263_bib47","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1056\/NEJMoa2201048","article-title":"ANCHOR investigators group. Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer","volume":"386","author":"Palefsky","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.tvr.2023.200263_bib48","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"26","key":"10.1016\/j.tvr.2023.200263_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci. Adv."},{"issue":"14","key":"10.1016\/j.tvr.2023.200263_bib50","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.tvr.2023.200263_bib51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/14760584.2021.1875824","article-title":"COVID-19 vaccine: where are we now and where should we go?","volume":"20","author":"Soleimanpour","year":"2021","journal-title":"Expert Rev. Vaccines"},{"issue":"9","key":"10.1016\/j.tvr.2023.200263_bib52","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect. Dis."}],"container-title":["Tumour Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666679023000101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666679023000101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:54:29Z","timestamp":1763006069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666679023000101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":49,"alternative-id":["S2666679023000101"],"URL":"https:\/\/doi.org\/10.1016\/j.tvr.2023.200263","relation":{},"ISSN":["2666-6790"],"issn-type":[{"value":"2666-6790","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is immunotherapy a potential game changer in managing human papillomavirus (HPV) infection and intraepithelial neoplasia?","name":"articletitle","label":"Article Title"},{"value":"Tumour Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tvr.2023.200263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"200263"}}